GlassScriptPhysician profile
John D Kolstoe
NPI 1124043229
$8,524.39
in general payments reported to CMS, 2019-2025
29 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.19 · 2022: $2,931 · 2023: $2,035 · 2024: $1,971 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,357 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,356.91 |
| Education | $149.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,647.86 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $1,367.09 | 2022-2025 | Evenity, Tavneos, Prolia |
| Novartis Pharmaceuticals Corporation | $823.16 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $606.58 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $330.04 | 2021-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $290.83 | 2023-2025 | Orencia |
| Ucb, INC. | $285.84 | 2022-2025 | Bimzelx |
| Abbvie INC. | $284.44 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $221.08 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.79 | 2022-2025 | Ofev, Spevigo |
| Fresenius Kabi USA, LLC | $188.06 | 2023-2025 | Idacio |
| Mallinckrodt Hospital Products INC. | $185.45 | 2022-2024 | Acthar |
| Radius Health, INC. | $173.49 | 2023-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $168.45 | 2022-2023 | Lupkynis |
| Organon LLC | $113.88 | 2023-2025 | Renflexis, Hadlima |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.54 | 2021-2022 | |
| Sobi, INC | $93.46 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $76.78 | 2022-2025 | Strensiq, Ultomiris |
| Sandoz INC. | $63.41 | 2023-2025 | Hyrimoz, Jubbonti |
| Alvogen INC | $61.00 | 2022-2025 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $39.57 | 2022-2023 | Opsumit, Uptravi |
| Bioventus LLC | $37.22 | 2022-2025 | Gelsyn-3 |
| Glaxosmithkline, LLC. | $36.92 | 2022-2023 | Benlysta |
| Genzyme Corporation | $32.65 | 2023 | |
| Horizon Therapeutics Plc | $30.29 | 2022-2023 | Krystexxa |
| Kiniksa Pharmaceuticals International, Plc | $20.87 | 2024 | Arcalyst |
| Mylan Institutional INC. | $19.81 | 2023 | |
| Genentech USA, INC. | $19.19 | 2024 | Actemra |
| Scilex Pharmaceuticals INC. | $18.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kolstoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.